Compare Amphastar Pharmaceuticals Inc (AMPH) vs Angi Inc (ANGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Angi Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Angi Inc trades at $4.5 (market cap $186.15M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 4.6× Angi Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | ANGI | |
|---|---|---|
Market Cap | $863.95M | $186.15M |
Sector | Health | Media |
52-Week High | $30.81 | $18.46 |
52-Week Low | $16.87 | $4.59 |
Enterprise Value | $1.26B | $395.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ANGI trades at $4.84, down 2.42% on the day, with a bearish technical signal and mixed earnings history. Revenue has declined from $1.9B in 2022 to $1.03B in 2025, though net income turned positive in 2024-2025 before a projected loss in 2026. The stock trades at low valuation multiples (P/E 14.81, P/S 0.21), but faces challenges with negative ROE and ROA. Recent news highlights Q2 2026 earnings misses and ongoing investigations into the company.
The outlook is cautious due to declining revenue, accelerating pro user churn, and negative cash flow projections. Analyst consensus is a $7.00 price target with a 'Hold' bias, but risks include platform deterioration, legal scrutiny, and lack of clear catalysts. Upside depends on stabilizing the core marketplace and executing a viable AI strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →
